Palvella Therapeutics to Host Full Year 2025 Financial Results Conference Call and Provide a Corporate Update on March 31, 2026

Rhea-AI Summary

Palvella Therapeutics (Nasdaq: PVLA) will report full year 2025 financial results before market open on Tuesday, March 31, 2026 and will host a conference call and corporate update at 8:30 a.m. ET the same day.

Investors can access a live webcast with slides via the company's Events & Presentations page; a replay will be available about two hours after the call and archived for 90 days.

News Market Reaction – PVLA

-0.69%

1 alert

-0.69% Session close to close

$1.67B Market Cap

0.4x Rel. Volume

In the Mar 24 session, PVLA declined 0.69%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement sets the timetable for full year 2025 results on March 31, 2026 and a corporate up...

Analysis

This announcement sets the timetable for full year 2025 results on March 31, 2026 and a corporate update call at 8:30 a.m. ET, continuing PVLA’s pattern of regular earnings communications. Historical “conferences,earnings” notices have led to modest average moves of about 0.84%. Investors may focus on how upcoming results relate to recent Phase 3 data, financing activity, and cash disclosures, with the 90‑day replay offering time to review management’s commentary.

Key Figures

Results date: March 31, 2026 Call time: 8:30 a.m. ET Webcast replay delay: 2 hours +1 more

4 metrics

Results date March 31, 2026 Full year 2025 financial results release before market open

Call time 8:30 a.m. ET Investor conference call and corporate update

Webcast replay delay 2 hours Approximate time after call before replay is available

Replay archive period 90 days Duration webcast replay remains on Events & Presentations page

Previous Conferences,earnings Reports

4 past events · Latest: Nov 04 (Neutral)

Same Type Pattern 4 events

Date	Event	Sentiment	24h Move	Catalyst
Nov 04	Q3 2025 call setup	Neutral	-2.3%	Scheduled Q3 2025 results and update call with webcast and replay details.
Aug 07	Q2 2025 call setup	Neutral	-0.1%	Announced Q2 2025 earnings call and corporate update with access information.
May 08	Q1 2025 call setup	Neutral	+4.4%	Scheduled Q1 2025 financial results and update call with webcast replay.
Mar 18	FY 2024 call setup	Neutral	+1.3%	Set full year 2024 results date and investor call with 90‑day archive.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Earnings/conference call scheduling has historically led to modest, mixed price reactions around PVLA, without a consistent directional pattern.

Recent Company History

Recent PVLA history shows repeated announcements of quarterly and full-year results calls, such as Q1, Q2, Q3 2025 and full-year 2024, each paired with a corporate update and 90‑day webcast replay access. Price reactions around these events ranged from about -2% to +4%, indicating that simple scheduling of earnings and update calls has produced only modest moves. Today’s full year 2025 call notice on March 31, 2026 fits this established communication pattern.

Key Terms

fda

1 terms

fda regulatory

"for which there are no U.S. Food and Drug Administration (FDA)-approved therapies"

The FDA is the U.S. federal agency that evaluates and approves medical drugs, devices, biological therapies and certain foods; think of it as the gatekeeper that decides whether a medical product is safe and effective for patients. For investors, FDA decisions determine whether a company can sell a product, affect expected revenue and introduce regulatory risk, so approvals, rejections or safety warnings can quickly move a company's valuation and stock price.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WAYNE, Pa., March 24, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (“Palvella” or “the Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced that the Company will report its full year 2025 financial results before market open on Tuesday, March 31, 2026. Palvella management will host a conference call for investors at 8:30 a.m. ET on that same day to discuss the results and provide a corporate update.

To access the live webcast of the call with slides, please click here or visit the "Events & Presentations" section of Palvella’s website. To access the call by phone, please use this registration link, and you will be provided with dial in details. A replay of the webcast will be available approximately 2 hours after the conclusion of the call and archived for 90 days under the "Events & Presentations" section of the Company's website at www.palvellatx.com.

About Palvella Therapeutics

Founded and led by rare disease biotech veterans, Palvella Therapeutics, Inc. (Nasdaq: PVLA) is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Palvella is developing a broad pipeline of product candidates based on its patented QTORIN™ platform, with an initial focus on serious, rare skin diseases and vascular malformations, many of which are lifelong in nature. Palvella’s lead product candidate, QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin), is currently being developed for the treatment of microcystic lymphatic malformations, cutaneous venous malformations, and clinically significant angiokeratomas. Palvella’s second product candidate, QTORIN™ pitavastatin, is currently being developed for the treatment of disseminated superficial actinic porokeratosis. For more information, please visit www.palvellatx.com or follow Palvella on LinkedIn or X (formerly known as Twitter).

QTORIN™ rapamycin and QTORIN™ pitavastatin are for investigational use only and neither has been approved by the FDA or by any other regulatory agency for any indication.

Contact Information

Investors
Wesley H. Kaupinen
Founder and CEO, Palvella Therapeutics
wes.kaupinen@palvellatx.com

Media
Marcy Nanus
Managing Partner, Trilon Advisors LLC
mnanus@trilonadvisors.com

FAQ

When will Palvella (PVLA) report full year 2025 results and hold its investor call?

Palvella will report full year 2025 results before market open on March 31, 2026. According to the company, management will host the investor conference call and corporate update at 8:30 a.m. ET that same day.

How can investors access the Palvella (PVLA) March 31, 2026 webcast and slides?

Investors can access the live webcast and slides via the company's Events & Presentations webpage. According to the company, the webcast link and slides will be available on Palvella's investor site for the live event.

Is there a replay available for Palvella's (PVLA) March 31, 2026 call and how long is it archived?

Yes. A replay of the webcast will be available about two hours after the call concludes. According to the company, the replay will be archived for 90 days under Events & Presentations on the website.

How do I join the Palvella (PVLA) conference call by phone on March 31, 2026?

To join by phone, register using the company's provided registration link to receive dial-in details. According to the company, registrants will be provided the phone number and access code to participate live.

What topics will Palvella (PVLA) cover on the March 31, 2026 investor call?

The company will discuss full year 2025 financial results and provide a corporate update during the call. According to the company, management intends to review results and corporate developments relevant to investors.